No GLP-1 medication is FDA-approved to treat prediabetes. Semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) are approved for chronic weight management or type 2 diabetes — not for the earlier, reversible stage in between. That said, prediabetes and GLP-1 eligibility can genuinely overlap: many people with prediabetes also carry excess weight that independently qualifies them for weight-management therapy, and a licensed clinician is the one who sorts out whether that applies to you.
The one-paragraph version
Prediabetes itself isn't an FDA-approved reason to prescribe a GLP-1. What often connects them is weight — a person with prediabetes and a BMI of 30+ (or 27+ with another weight-related condition) may independently qualify for Wegovy® or Zepbound® under their actual approved criteria. First-line prediabetes management is lifestyle change: diet, activity, and weight loss have the longest, strongest evidence base for preventing progression to type 2 diabetes. Whether medication fits into your specific picture is a clinical decision, not a given.
What prediabetes actually means
Prediabetes is a lab-defined stage where blood sugar is higher than normal but hasn't crossed the threshold into type 2 diabetes. The American Diabetes Association defines it using any of three tests: an A1C of 5.7-6.4%, a fasting plasma glucose of 100-125 mg/dL, or a 2-hour reading of 140-199 mg/dL on an oral glucose tolerance test. It's common — a large share of U.S. adults meet at least one of these criteria — and it's frequently found incidentally, on routine bloodwork, rather than through symptoms, since prediabetes usually doesn't cause any.
The reason it gets attention is that it's a genuine inflection point. Left unaddressed, a meaningful share of people with prediabetes go on to develop type 2 diabetes within several years. But the stage is also named "pre" for a reason: it's often reversible, and the evidence for reversing it predates GLP-1 medications by two decades.
Is a GLP-1 medication FDA-approved for prediabetes?
No. Wegovy® and Zepbound® are FDA-approved for chronic weight management in adults with obesity (BMI ≥30), or overweight (BMI ≥27) plus at least one weight-related condition such as hypertension, dyslipidemia, or cardiovascular disease. Ozempic® and Mounjaro® are FDA-approved for type 2 diabetes. None of the four carries an FDA-approved indication for prediabetes, and neither do compounded semaglutide or tirzepatide preparations.
That distinction matters in practice. A clinician doesn't prescribe a GLP-1 because someone has prediabetes; they prescribe it because that person independently meets the medication's actual approved weight or diabetes criteria — and prediabetes, plus the rest of the clinical picture, becomes one input into that decision, not a qualifying diagnosis on its own.
Why lifestyle change comes first
Prediabetes has one of the best-studied non-drug evidence bases in all of preventive medicine. The Diabetes Prevention Program, a landmark randomized trial, found that an intensive lifestyle intervention — modest weight loss plus 150 minutes of weekly activity — reduced progression to type 2 diabetes by 58% over about three years, outperforming metformin, which reduced progression by 31% in the same trial. That's why the ADA's Standards of Care names structured lifestyle intervention as the first-line approach for prediabetes, with metformin considered for higher-risk patients (younger, higher BMI, or a history of gestational diabetes) who don't respond adequately.
What this article is not saying
No semaglutide or tirzepatide trial has been designed or FDA-reviewed specifically to measure progression from prediabetes to type 2 diabetes. This piece isn't claiming GLP-1 therapy prevents diabetes in a prediabetes population — that hasn't been established. It's describing how weight-management eligibility and a prediabetes diagnosis can independently coexist.
When might a clinician consider medication?
| Approach | What it's approved for | Role in prediabetes |
|---|---|---|
| Lifestyle intervention | N/A | First-line for everyone with prediabetes, per ADA guidance |
| Metformin | Type 2 diabetes; long-standing off-label prediabetes use | Considered for higher-risk patients when lifestyle change alone isn't enough |
| Semaglutide / tirzepatide (compounded or brand) | Chronic weight management or type 2 diabetes | Considered when weight criteria are independently met; not a prediabetes-specific approval |
If someone with prediabetes also has a BMI and health history that meet Wegovy®'s or Zepbound®'s actual approved criteria, a clinician can prescribe on that basis — the weight-management indication, with prediabetes as relevant context, not the reason itself. If diabetes-range labs are found, Ozempic® or Mounjaro® enter the conversation under their own type 2 diabetes indication. A clinician who documents a specific clinical rationale can also consider a compounded preparation under FDCA §503A, when a brand-name product isn't the right fit for a given patient.
How a clinician evaluates eligibility
- Confirm the diagnosis with real labs. A1C, fasting glucose, or an OGTT — not just a family history or a hunch.
- Check whether weight-management criteria are independently met. BMI thresholds and any weight-related comorbidities are what actually drive GLP-1 eligibility, separate from the prediabetes finding.
- Try or reassess lifestyle intervention first. What's already been attempted, for how long, and with what result.
- Screen for the same contraindications as anyone else. Personal or family history of medullary thyroid carcinoma or MEN2, pregnancy plans, and other standard screening questions apply regardless of the prediabetes diagnosis.
- Set a monitoring plan. A1C and weight tracked over time, since prediabetes management is a longitudinal effort, not a one-time prescription.
Where Pallas fits
Your Pallas intake captures your labs, weight history, and any prior attempts at lifestyle change. A US-licensed clinician reviews that information and determines whether you meet the actual approved criteria for GLP-1 therapy — chronic weight management or type 2 diabetes — and, if so, whether a brand-name or compounded option fits your situation. Prediabetes on its own isn't a qualifying diagnosis for a GLP-1, and a responsible clinician will tell you plainly if it doesn't apply to you.
Pallas offers both FDA-approved and compounded medications. Compounded medications are not FDA-approved and are not generic versions of brand-name drugs. Eligibility and treatment are determined by a US-licensed clinician; results vary. Private pay only (no insurance). Operated by Brentmoor, Inc.
Frequently asked questions
No. Semaglutide (Wegovy®, Ozempic®) and tirzepatide (Zepbound®, Mounjaro®) are FDA-approved for chronic weight management or type 2 diabetes — not for prediabetes. Compounded semaglutide and tirzepatide are also not approved for prediabetes. A person with prediabetes may still qualify for GLP-1 therapy, but only by independently meeting the medication's actual approved weight-management or diabetes criteria.
Yes, generally — the ADA's Standards of Care names structured lifestyle intervention (weight loss and regular activity) as first-line for prediabetes, and it has the longest evidence base of any approach for reducing progression to type 2 diabetes. Medication, when appropriate, is layered on top of that foundation, not a replacement for attempting it first.
They're different tools with different evidence bases. Metformin has decades of use specifically for prediabetes, particularly in higher-risk patients, and remains a common first medication when lifestyle change alone isn't enough. A GLP-1 is approved for weight management or type 2 diabetes and is sometimes considered when a patient's weight independently meets those criteria — not as a prediabetes-specific treatment. Which approach fits you is a decision for your prescriber based on your labs and history.
No semaglutide or tirzepatide trial has been designed or FDA-reviewed specifically to measure progression from prediabetes to type 2 diabetes, so that claim hasn't been established. What is well established is that lifestyle intervention and, to a lesser extent, metformin reduce that progression — the Diabetes Prevention Program found intensive lifestyle change reduced it by 58% over about three years. A GLP-1 prescribed for independently qualifying weight or diabetes criteria may support the same underlying goals, but it isn't a studied diabetes-prevention treatment.
None on their own — prediabetes labs (an A1C of 5.7-6.4%, for example) don't by themselves meet any GLP-1's approved criteria. Eligibility comes from the weight-management thresholds (generally a BMI of 30+, or 27+ with a weight-related condition) or a type 2 diabetes diagnosis. Your clinician reviews your labs alongside your weight history and overall health to determine whether you meet either bar.
References
- American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl 1).
- Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin (Diabetes Prevention Program). N Engl J Med. 2002;346(6):393-403.
- Wegovy® (semaglutide) prescribing information. Novo Nordisk.
Bottom line: No GLP-1 medication is FDA-approved to treat prediabetes. Lifestyle change has the longest, strongest evidence base for reversing it, and remains first-line. Weight is the real overlap — a person with prediabetes may separately qualify for GLP-1 therapy if they independently meet its actual approved weight-management or diabetes criteria. A licensed clinician sorts out whether that's you.
Have prediabetes and wondering about a GLP-1?
Share your labs, weight history, and what you've already tried in a 5-minute intake. A US-licensed clinician will review whether GLP-1 treatment applies to your situation — and tell you plainly if it doesn't.
Start your intake →For a related condition-specific guide, see can GLP-1 medications help with PCOS? If midlife weight changes are part of your picture, read why weight gain accelerates after 45, or learn more on our GLP-1 treatment overview.